CD274 and neoplasm: Tumor heterogeneity, divergent immune and tumor cell expression of PD-L1, and diverse immunohistochemistry (IHC) assays and scoring methods make sole use of PD-L1+ unreliable as a predictive biomarker of response [14–16].